Temenos Benchmarks Its Cloud-native Digital Banking Software on AWS and Proves Its Ability to Handle Over Half the World’s Banking Transaction Volumes on a Single Instance of the Software
21.11.2019 11:30:00 EET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced its high water benchmark performance results for cloud-native, cloud-agnostic Temenos T24 Transact, the next generation core banking product and Temenos Infinity, the breakthrough digital front office product in a benchmark exercise with Amazon Web Services (AWS). In the benchmark test of its microservices architecture, Temenos processed 50K transactions per second (TPS), and demonstrated its ability to elastically scale up and down based on business demand, ensuring banks only pay for the resources they use and benefit from up to 10x lower infrastructure costs.
The benchmark validates that Temenos T24 Transact running on AWS Cloud, using NuoDB database technology, the in-memory distributed SQL database, enables banks to benefit from unlimited processing capacity and lower total cost of ownership (TCO) enabled by AWS. The benchmark demonstrates 100x faster response times to client requests with its microservices architecture. Temenos continually invests in R&D to leverage new technologies that deliver lower TCO and tangible business benefits to banks. The company has a strategic partnership and a minority stake in NuoDB.
Key benchmark highlights:
- Highly scalable performance: Temenos’ digital banking platform exceeded 50K TPS, enabling banks to build scalable, highly secure applications that take advantage of the agility and cost benefits of the cloud.
- Lower TCO: Auto-scaling allows banks to only pay for the active workload rather than always paying for the maximum potential workload through dynamic deployment of containers.
- Modern architecture: Achieved with Temenos’ cloud-native Temenos T24 Transact, Temenos Infinity, Data Event Streaming and microservices architecture.
- Cloud-native: Temenos architecture leverages cloud-native technologies such as AWS Lambda functions, Amazon DynamoDB and Amazon Kinesis data streams.
The banking industry is witnessing an unprecedented growth in online transactions, led by new digital channels, open banking and new technologies. Digital banking is driving global transaction volumes away from cash and increases the look-to-book ratio. According to CapGemini non-cash transactions grew globally by 12% during 2016-2017 and reached 539 billion, the highest in the past two decades. Based on these calculations, Temenos’ benchmark proves its ability to handle over half the world’s banking transaction volumes on a single instance of the software. Furthermore, consolidation in the banking industry results in the creation of mega banks with even higher demands in transaction processing.
Max Chuard, CEO, Temenos, commented: “This benchmark highlights Temenos’ relentless innovation and investment in cloud technology. Cloud is becoming a game-changer, enabling banks to accelerate their digital transformation and optimize performance and cost. Temenos has always given the banking community greater choice of next-generation cloud technologies working with NuoDB and all major cloud providers. We have achieved Advanced Technology Partner status in the AWS Partner Network and have collaborated to meet the needs of banks of all sizes, including top tier banks. The benchmark results with AWS demonstrate that our modern, cloud-native, cloud-agnostic architecture, coupled with a distributed database, elastically scales allowing banks to benefit from operational efficiencies and significantly lower infrastructure costs. We can support the highest volumes of transactions and operational requirements of any bank in the world now and in the future.”
Bob Walmsley, President and CEO, NuoDB: “Temenos’ commitment to innovation and research is fundamental to the advances we’ve made in this latest benchmark. Our joint development enables Temenos customers to achieve lower TCO for the solution using our distributed SQL database to dynamically scale in and out to align with the variable workloads inherent to banking application requirements.”
Temenos has been pioneering in the cloud since 2011 and the results of this benchmark are yet another first. Temenos was the first software provider to put a core banking system in the public cloud and the first to launch a payment hub, fully embedded into a core banking platform, in the cloud. Temenos has deployed more banks in the cloud than any other vendor.
– Ends –
About Temenos
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005336/en/
Contact information
Media Contacts
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email:
allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
